← Leaderboards
Ajit K Parhi
Taxis Pharmaceuticals, Inc.
$2,799,789
Attributed
$2,799,789
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.9M · FY2024–25$2M$1.5M$1M$500K$0
'24
'25
Funding mix
By agency
NIH$2,799,789 · 2
By mechanism
R44$2,799,789 · 2
Top collaborators
No co-investigators on record.
Others in their field
Other Rising Stars on “In Vivo”
- Michael Difilippantonio · Leidos Biomedical Research, Inc.$22,364,766
- Sabrina Paganoni · Massachusetts General Hospital$17,050,216
- Suma Babu · Massachusetts General Hospital$17,050,216
- Kevin V Grimes · Stanford University$14,783,804
- Xuping Xie · University Of Texas Med Br Galveston$13,737,799
- Heinz Ernst Moser · University Of Texas Med Br Galveston$12,973,432
Research focus
In VivoNephrotoxicityExhibitsIn VitroLead OptimizationMulti-Drug ResistanceClinical DevelopmentEvaluationGenotoxicityInhibitorDoseLeadDrug KineticsMaximum Tolerated DoseAntibioticsAcute ToxicityAntimicrobialCytotoxicityExperimental StudyGeneticCardiotoxicityInfectionAnalogPathogen
Grant awards (3)
Lead optimization of oral DHFR inhibitor for the treatment of multidrug-resistant N. gonorrhoeae infections.$1,000,000
R44 · FY2025 · AI · contact PI
Lead optimization of a novel cyclic aryl-indole efflux pump inhibitor (EPI) series in combination with levofloxacin against Pseudomonas aeruginosa$889,610
R44 · FY2025 · AI · contact PI
Lead optimization of a novel cyclic aryl-indole efflux pump inhibitor (EPI) series in combination with levofloxacin against Pseudomonas aeruginosa$910,179
R44 · FY2024 · AI · contact PI